Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced that its representatives will attend the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum provides a platform for experts in nasal drug development to discuss innovations and challenges in the field. Silo Pharma's participation highlights its ongoing efforts to advance SPC-15, a novel therapeutic designed to deliver drugs directly from the nose to the brain, targeting the treatment of post-traumatic stress disorder (PTSD).
The announcement comes as Silo Pharma continues to progress its pipeline, with SPC-15 emerging as a lead candidate. The company's CEO, Eric Weisblum, emphasized the importance of the forum in fostering collaboration and knowledge exchange. "This forum offers a valuable opportunity to engage with leaders in nasal drug development as we continue to advance SPC-15's nose-to-brain approach," said Weisblum. The unique delivery method aims to enhance the efficacy of treatment by bypassing the blood-brain barrier, potentially offering faster relief and improved outcomes for patients suffering from PTSD.
Silo Pharma recently reported positive preclinical data for SPC-15, demonstrating that the formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data was consistent and aligned with long-term stability results, indicating the product's robustness and commercial viability. These findings are critical as the company moves toward clinical development and eventual regulatory approval.
The IPAC-RS forum is a key event for companies and researchers involved in inhalation and nasal drug products. Silo Pharma's presence there underscores its commitment to staying at the forefront of drug delivery innovation. The company is also exploring other therapeutic applications, including chronic pain and central nervous system diseases, but SPC-15 remains a focal point due to its potential to address a significant unmet medical need in mental health.
PTSD affects millions of people worldwide, and current treatments are often limited by side effects or delayed onset of action. Silo Pharma's approach could represent a significant advancement, offering a non-invasive, targeted therapy that acts quickly. The company's collaboration with leading universities and research institutions strengthens its scientific foundation and may accelerate the development process.
Investors and industry observers will be watching closely as Silo Pharma presents at the forum, seeking updates on the progress of SPC-15 and potential next steps. The company's participation in such events is a testament to its active engagement with the scientific community and its dedication to bringing innovative therapies to patients.
For more information about Silo Pharma and its pipeline, visit the company's website at silopharma.com or stay updated with the latest news in their newsroom at IBN's newsroom.
